La Jolla Pharmaceutical Company Receives Orphan Designation

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
La Jolla Pharmaceutical Company Receives Orphan Designation From FDA

SAN DIEGO, CA--(Marketwired - Jul 17, 2013) - La Jolla Pharmaceutical Company ( OTCBB : LJPC ) ("La Jolla" and "Company"), a leader in the development of therapeutics targeting life threating diseases , announced today that the FDA Office of Orphan Products Development has granted an "Orphan Drug" designation to La Jolla's drug candidate LJPC-0712 for treatment of Niemann-Pick type C disease.

"Having received a second orphan designation from FDA, our team continues to build La Jolla into a leader in the development of treatments for life threating diseases," said George Tidmarsh, MD, PhD, President and Chief Executive Officer of La Jolla. "We remain dedicated to developing novel treatments to help those suffering with unmet debilitating and fatal diseases."

Niemann-Pick type C disease (NP-C) is a rare inherited disease caused by mutations in either the NPC1 (95% of cases) or of the NPC2 gene. These mutations lead to impaired intracellular lipid trafficking with subsequent accumulation of cholesterol and glycosphingolipids in the brain and other tissues. Patients come to medical attention with a range of symptoms, neurologic signs, age of onset and rate of progression. Characteristic neurological manifestations include abnormal eye movements, unbalanced gait, abnormal speech, or difficulty swallowing. Epileptic seizures are also common. Typically, onset occurs in childhood, however adults are increasingly being diagnosed with late onset neurologic symptoms or psychiatric manifestations. The age of onset of neurologic symptoms is used to categorize patients and can be useful in evaluation and treatment planning. In general, patients diagnosed earlier in age progress more rapidly and have a shorter survival than those diagnosed later in life. Patients with NP-C have an estimated median survival of less than 20 years.

LJPC-0712 is commonly known as allopregnanolone. Allopregnanolone is a neurosteroid present in the blood and brain. It is a metabolite of progesterone and potent modulator of gamma-aminobutyric acid ( GABAA ) receptors. It increases the activity of endogenous GABA by allosteric modification of the GABA A receptor. Allopregnanolone has pharmacological properties similar to other positive modulators of GABA A receptors, including anti-anxiety and anti-seizure activity.

Allopregnanolone is synthesized from cholesterol and due to disrupted cholesterol biosynthesis levels are altered in NP-C. Because allopregnanolone and related steroid hormones promote neuron health and development, reduced levels of allopregnanolone in NP-C likely contribute to the neurologic deterioration associated with NP-C. End-product replacement therapy targets the final products of a metabolic pathway that are deficient in a disease state. Therefore, replacement therapy with allopregnanolone represents a potential treatment for NP-C. Treatment of animals genetically modified to replicate NP-C with allopregnanolone supports this theory with treated animals showing improvement in many disease characteristics.

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company dedicated to the development of medical treatments that significantly improve outcomes in patients with life-threatening diseases. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer, currently being tested in a Phase 2 clinical trial for the treatment of chronic kidney disease. For more information on the Company please visit http://www.ljpc.com .

Forward-Looking Statement Safe Harbor

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause actual results to be materially different from these forward-looking statements. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the U.S. Securities and Exchange Commission ("SEC"), all of which are available free of charge on the SEC's web site http://www.sec.gov . These risks include, but are not limited to, risks relating to the development of GCS-100 and LJPC-501, the success and timing of future preclinical and clinical studies of this compound, and potential indications for which GCS-100 and LJPC-501 may be developed. Subsequent written and oral forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's reports filed with the SEC. The Company expressly disclaims any intent to update any forward-looking statements.

Company Contact George F. Tidmarsh, M.D., Ph.D. President & Chief Executive Officer La Jolla Pharmaceutical Company Phone: (858) 207-4264 Email: GTidmarsh@ljpc.com And Chester S. Zygmont, III Director of Finance La Jolla Pharmaceutical Company Phone: (858) 207-4262 Email: czygmont@ljpc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 184

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 159

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Airtel Money Upgrade Raises the Stakes in East Africa

Updated Category News Views 0

Mobile money lives or dies in the irritating little moments: a transfer that hangs, a menu that makes people punch five buttons too many, a merchant payment that simply will not clear. Airtel Money is attacking that friction in Malawi and Tanzania with an enhanced platform from Comviva, and this is more consequential than the usual software-refresh chest thumping. In...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 197

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
Max y Noelia Explore Trade at 9th CIIE in Shanghai

Updated Category News Views 126

Influencers at the Heart of Global Trade Exploration Makin' their debut on the big stage of the 9th China International Import Expo (CIIE), Mexican influencers Max y Noelia found themselves caught in a whirlwind of trade and cultural exchanges over in Shanghai. These digital mavens aren't just snapping selfies. Nope, they're capturing the very essence of international...

Continue Reading
Vusion's 2030 Plan Puts Recurring Revenue First At Scale

Updated Category News Views 20

Shelf labels are not exactly romance, yet Vusion has turned them into a serious growth machine. The 2030 plan is not really about hanging more electronic displays in aisles; it is about making those displays, sensors and store connections produce software and service revenue for years. That is the part of this story worth watching. The Hardware Base Is Becoming the Hook...

Continue Reading
Tim Hortons Bets on ELF Cheer for U.S. Holiday Visits

Updated Category News Views 0

Nothing says holiday restaurant marketing quite like putting spaghetti-shaped whipped topping on hot chocolate and trusting a 2003 movie to do the selling. Tim Hortons is rolling out an ELF-inspired menu at participating U.S. locations starting November 18, 2026, pairing the chain with Warner Bros. Consumer Products and mining Buddy the Elf's sugar-fueled world for a...

Continue Reading
Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 147

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Sectra's RSNA AI Pitch Centers on Workflow, Not Hype

Updated Category News Views 95

Radiology has heard enough grand AI promises to fill a hospital basement, which makes Sectra's RSNA 2026 message refreshingly grounded. The Swedish imaging IT and cybersecurity company is putting its weight behind the unglamorous part of adoption: fitting AI into the daily diagnostic machinery without handing clinicians another awkward system to babysit. That is where...

Continue Reading
Markel Elevates War Risk Expertise in London Market

Updated Category News Views 67

A Specialty Desk Gets Its Own Weather Vane War and political violence underwriting is not a corner of insurance where a fancy title change can be shrugged off. The ground shifts under the policyholder, the broker and the carrier without much warning, and a bad call can sit on a book for years. Markel Insurance has named Chloe Gordge Director of War and Political Violence...

Continue Reading

Top 5 Most Recently Viewed Articles

Dover Set to Release Q2 2025 Earnings; Join the Conference Call

Updated Category News Views 156

Dover Set to Release Q2 2025 Earnings Dover is gearing up to share its financial results for the second quarter of 2025, scheduled for release at approximately 6:00 a.m. Central time on the upcoming Thursday. This significant event marks a crucial moment for shareholders and analysts alike, as they anticipate insights into the company's performance and strategic moves....

Continue Reading
Investigation of ImmunityBio, Inc. and Shareholder Rights

Updated Category News Views 322

Investigation of ImmunityBio, Inc. In recent developments, Bragar Eagel & Squire, P.C., a well-respected law firm specializing in shareholder rights, has launched an investigation regarding ImmunityBio, Inc. (NASDAQ: IBRX). This probe is geared towards looking into potential legal claims on behalf of long-term shareholders, aiming to ensure their interests are safeguarded...

Continue Reading
Norges Bank's Recent Stake Change in Syensqo Explained

Updated Category News Views 279

Norges Bank's Recent Notification Regarding Stake in Syensqo Norges Bank has recently communicated a significant change regarding its participation in Syensqo. This notification, in line with Belgian transparency laws, reveals that Norges Bank has crossed the 3% voting rights threshold, which is vital for all stakeholders. Understanding the Changes in Voting Rights The...

Continue Reading
ZyVersa Therapeutics Marks Progress with Promising Pipeline Updates

Updated Category News Views 232

Key Developments in ZyVersa's Clinical Journey Important Highlights: Announcement of a Phase 2a proof-of-concept clinical trial for Cholesterol Efflux Mediator™ VAR 200 focusing on patients with diabetic kidney disease planned for the first half of 2025. The regulatory framework for VAR 200’s primary indication, focal segmental glomerulosclerosis (FSGS), is set to...

Continue Reading
Bunion Surgery Market Growth and Leading Players Explained

Updated Category News Views 270

Overview of the Bunion Surgery Market The global Bunion Surgery Market is witnessing substantial growth, projected to increase from US$437.8 million in 2023 to an impressive US$606.1 million by 2029, achieving a CAGR of 5.7%. The surge in demand for surgical treatments primarily arises from the rising incidence of bunions, particularly among the aging population who are...

Continue Reading